Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.52 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
| ▸ | PYGB | P11216 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606624 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL15299087 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13542913 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8244688 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23816520 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14268507 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL24518019 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL147049 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13110610 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21610360 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018053706-A1 | COMPOSITION COMPRISING PAEONIFLORIN OR ALBIFLORIN ANALOGUE, METHOD OF PREPARATION THEREOF | L'OREAL (FR) | 2018-03-29 | — | — | WO | disclosed |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016176343-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20150166594-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-18 | — | — | US | disclosed |
| WO-2015077652-A1 | DESAZADESFERRITHIOCIN ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20140147471-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | COMVITA NEW ZEALAND LTD. (NZ) | 2014-05-29 | — | — | US | disclosed |
| US-8679499-B2 | Methods for relieving asthma-associated airway hyperresponsiveness | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8637287-B2 | Glycosyltransferase reversibility for sugar nucleotide synthesis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130295163-A1 | NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | EZAKI GLICO CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130295163-A1 | NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | EZAKI GLICO CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-09 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20100197613-A1 | METHODS FOR INHIBITION OF NKT CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-7682614-B2 | Methods for inhibition of NKT cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-03-23 | — | — | US | disclosed |
| US-7582426-B2 | Method for expression of proteins on spore surface | GENEOFOCUS CO., LTD. (KR) | 2009-09-01 | — | — | US | disclosed |
| US-7572604-B2 | Modified carbohydrate processing enzyme | ISIS INNOVATION LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20090181444-A1 | MODIFIED CARBOHYDRATE PROCESSING ENZYME | ISIS INNOVATION LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007079448-A2 | THREE COMPONENT CARBOHYDRATE VACCINE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070066814-A1 | Steroid modified chacotrioses and solatrioses | GLYCOMED SCIENCES LIMITED (KY) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LGALS1 1838/4885LGALS3 1512/4885LGALS9 1928/4885 |
| US-20150166594-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | MSN, MGAM, NISCH | LGALS1 4621/4885LGALS3 4497/4885LGALS9 4262/4885 |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | LGALS1 12/4885LGALS3 39/4885LGALS9 47/4885 |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | MSN, MGAM, NISCH | LGALS1 4621/4885LGALS3 4497/4885LGALS9 4262/4885 |
| US-20100197613-A1 | METHODS FOR INHIBITION OF NKT CELLS | UGCG, CD47, ASAH2 | LGALS1 42/4885LGALS3 85/4885LGALS9 70/4885 |
| US-20070066814-A1 | Steroid modified chacotrioses and solatrioses | HSD17B7, CYP17A1, HSD11B2 | LGALS1 1576/4885LGALS3 1283/4885LGALS9 3138/4885 |
| US-20140147471-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | CD14, IL2, CD74 | LGALS1 11/4885LGALS3 13/4885LGALS9 20/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LGALS1 1752/4885LGALS3 1484/4885LGALS9 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.